Annual SG&A
$21.08 M
+$12.37 M+142.06%
31 December 2023
Summary:
Acrivon Therapeutics Common Stock annual selling, general & administrative expenses is currently $21.08 million, with the most recent change of +$12.37 million (+142.06%) on 31 December 2023. During the last 3 years, it has risen by +$19.78 million (+1523.96%). ACRV annual SG&A is now at all-time high.ACRV Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$6.28 M
-$136.00 K-2.12%
30 September 2024
Summary:
Acrivon Therapeutics Common Stock quarterly selling, general & administrative expenses is currently $6.28 million, with the most recent change of -$136.00 thousand (-2.12%) on 30 September 2024. Over the past year, it has increased by +$406.00 thousand (+6.92%). ACRV quarterly SG&A is now -2.12% below its all-time high of $6.41 million, reached on 30 June 2024.ACRV Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$575.17 M
-$76.98 M-15.45%
30 September 2024
Summary:
Acrivon Therapeutics Common Stock TTM selling, general & administrative expenses is currently -$575.17 million, with the most recent change of -$76.98 million (-15.45%) on 30 September 2024. Over the past year, it has dropped by -$594.76 million (-3036.51%). ACRV TTM SG&A is now -2213.19% below its all-time high of $24.46 million, reached on 30 September 2024.ACRV TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACRV Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +142.1% | +6.9% | -3036.5% |
| 3 y3 years | +1524.0% | +415.7% | -10000.0% |
| 5 y5 years | - | - | - |
ACRV Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +1524.0% | -2.1% | +448.6% | -2213.2% | at low |
| 5 y | 5 years | at high | +1524.0% | -2.1% | +1279.3% | -2213.2% | at low |
| alltime | all time | at high | +1524.0% | -2.1% | +1279.3% | -2213.2% | at low |
Acrivon Therapeutics Common Stock Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $6.28 M(-2.1%) | $24.46 M(+1.7%) |
| June 2024 | - | $6.41 M(+3.5%) | $24.05 M(+6.2%) |
| Mar 2024 | - | $6.20 M(+11.1%) | $22.64 M(+7.4%) |
| Dec 2023 | $21.08 M(+142.1%) | $5.58 M(-5.0%) | $21.08 M(+7.6%) |
| Sept 2023 | - | $5.87 M(+17.4%) | $19.59 M(+27.6%) |
| June 2023 | - | $5.00 M(+7.9%) | $15.35 M(+25.8%) |
| Mar 2023 | - | $4.63 M(+13.5%) | $12.20 M(+40.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2022 | $8.71 M(+253.1%) | $4.08 M(+150.0%) | $8.71 M(+49.1%) |
| Sept 2022 | - | $1.63 M(-11.6%) | $5.84 M(+25.3%) |
| June 2022 | - | $1.85 M(+61.5%) | $4.66 M(+65.6%) |
| Mar 2022 | - | $1.14 M(-6.0%) | $2.82 M(+68.4%) |
| Dec 2021 | $2.47 M(+90.0%) | - | - |
| Dec 2021 | - | $1.22 M(+167.5%) | $1.67 M(+267.5%) |
| Sept 2021 | - | $455.00 K | $455.00 K |
| Dec 2020 | $1.30 M | - | - |
FAQ
- What is Acrivon Therapeutics Common Stock annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Acrivon Therapeutics Common Stock?
- What is Acrivon Therapeutics Common Stock annual SG&A year-on-year change?
- What is Acrivon Therapeutics Common Stock quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Acrivon Therapeutics Common Stock?
- What is Acrivon Therapeutics Common Stock quarterly SG&A year-on-year change?
- What is Acrivon Therapeutics Common Stock TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Acrivon Therapeutics Common Stock?
- What is Acrivon Therapeutics Common Stock TTM SG&A year-on-year change?
What is Acrivon Therapeutics Common Stock annual selling, general & administrative expenses?
The current annual SG&A of ACRV is $21.08 M
What is the all time high annual SG&A for Acrivon Therapeutics Common Stock?
Acrivon Therapeutics Common Stock all-time high annual selling, general & administrative expenses is $21.08 M
What is Acrivon Therapeutics Common Stock annual SG&A year-on-year change?
Over the past year, ACRV annual selling, general & administrative expenses has changed by +$12.37 M (+142.06%)
What is Acrivon Therapeutics Common Stock quarterly selling, general & administrative expenses?
The current quarterly SG&A of ACRV is $6.28 M
What is the all time high quarterly SG&A for Acrivon Therapeutics Common Stock?
Acrivon Therapeutics Common Stock all-time high quarterly selling, general & administrative expenses is $6.41 M
What is Acrivon Therapeutics Common Stock quarterly SG&A year-on-year change?
Over the past year, ACRV quarterly selling, general & administrative expenses has changed by +$406.00 K (+6.92%)
What is Acrivon Therapeutics Common Stock TTM selling, general & administrative expenses?
The current TTM SG&A of ACRV is -$575.17 M
What is the all time high TTM SG&A for Acrivon Therapeutics Common Stock?
Acrivon Therapeutics Common Stock all-time high TTM selling, general & administrative expenses is $24.46 M
What is Acrivon Therapeutics Common Stock TTM SG&A year-on-year change?
Over the past year, ACRV TTM selling, general & administrative expenses has changed by -$594.76 M (-3036.51%)